Supply of the product Pneumovax 23

Overview

The Therapeutic Goods Act 1989, enacted to regulate therapeutic goods in Australia, was introduced to address the need for a cohesive framework to ensure the safety, efficacy, and quality of these products. This Act empowers the Therapeutic Goods Administration (TGA) to oversee the regulation and approval of therapeutic goods, including medicines, medical devices, and blood products. The Act aims to protect public health by ensuring that therapeutic goods meet acceptable standards of quality and safety. The Act was passed by the Parliament of Australia to establish a systematic approach to managing therapeutic goods, thereby closing gaps in previous legislative arrangements. The policy objective underpinning the Act is to facilitate the availability of quality, safe, and effective therapeutic goods while safeguarding public health.

Scope and Application

The Therapeutic Goods Act 1989 applies to all therapeutic goods, including medicines, medical devices, and blood and blood components, within Australia. The Act regulates the import, manufacture, supply, and advertising of these goods, with the overarching aim of ensuring that therapeutic goods available in Australia meet acceptable standards of quality, safety, and efficacy. The Act applies to individuals and entities involved in the supply chain of therapeutic goods, including manufacturers, importers, and distributors. The Act’s jurisdiction is national, applying across all states and territories in Australia. While the Act broadly governs therapeutic goods, it includes specific exclusions such as food, cosmetics, and most devices used solely for personal use that do not pose a risk to health and safety. The Therapeutic Goods Act 1989 extends its application through various subordinate instruments, such as therapeutic goods regulations and orders, which provide detailed specifications and requirements for different categories of therapeutic goods. These instruments often include provisions for exemptions and thresholds, allowing certain products to be exempt under specific conditions or to meet reduced regulatory requirements if they are considered lower risk.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) includes sections 14 and 14A, which allow for the delegate of the Secretary of the Department of Health to give consent for the importation and supply of therapeutic goods that do not fully comply with certain regulations, under specific conditions. In this case, section 14 of the Act has been applied, granting consent for the importation and supply of PNEUMOVAX 23 pneumococcal purified capsular polysaccharides 25 microgram/0.5mL injection pre-filled syringe (AUSTR 222235) by Merck Sharp & Dohme Australia Pty Ltd. This consent was issued on 28 May 2014, and it permits the product to be supplied despite not conforming to the Therapeutic Goods Order No. 69 - General requirements for labels for medicines, specifically regarding letter height and the inclusion of all active ingredient names on the syringe labels. Entities and parties governed by the Act, such as Merck Sharp & Dohme Australia Pty Ltd in this instance, are required to ensure that any therapeutic goods they intend to import or supply are compliant with all relevant regulations unless they receive specific consent under the Act. This consent comes with conditions, such as ensuring that the product complies with all other applicable parts of the Therapeutic Goods Order No. 69 and other relevant standards. This means that while the specific non-compliance regarding label requirements has been addressed by the consent, the product must still meet all other regulatory standards to be legally supplied. Failure to adhere to the conditions set by the consent granted under sections 14 and 14A of the Act could lead to various consequences. Under section 15(1) of the Act, the delegate of the Secretary has made the consent subject to conditions, and non-compliance with these conditions could result in enforcement actions. The Act provides for both civil and criminal penalties for breaches, although specific penalties are not detailed in the provided text. Generally, under the Act, civil penalties can include fines up to several thousand Australian dollars, while criminal offences can lead to more severe penalties, including substantial fines and imprisonment, depending on the nature and severity of the breach. In summary, section 14 and 14A of the Therapeutic Goods Act 1989 allow for consent to be given for the importation and supply of therapeutic goods that do not fully comply with certain regulations, provided that specific conditions are met. The obligations imposed on entities like Merck Sharp & Dohme Australia Pty Ltd include ensuring compliance with all other applicable standards and regulations. Breaches of these conditions can result in both civil and criminal consequences, including fines and imprisonment, although the exact penalties depend on the nature of the breach.